A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

This early-phase trial tests a new drug called ONM-501 — injected directly into tumors — alone and in combination with the immunotherapy drug cemiplimab, in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older with an advanced solid tumor or lymphoma that has progressed on standard therapies - You have at least one tumor that can be injected and measured - Your liver, kidney, and blood function are adequate - You have HIV but are on stable antiretroviral therapy with controlled viral levels **You may NOT be eligible if...** - You had another cancer within the past 2 years (excluding certain minor skin cancers or cervical carcinoma in situ) - You had major surgery within 4 weeks - You have uncontrolled high blood pressure or recent major cardiovascular events - You are pregnant or breastfeeding - You have active infection requiring treatment or are on another clinical trial - You have untreated brain metastases or tumors near the brainstem or meninges Talk to your doctor to see if this trial is right for you.